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Primary balloon angioplasty of small (2 mm)
cephalic veins improves primary patency of
arteriovenous fistulae and decreases reintervention
rates
Pierfrancesco Veroux, MD,a Alessia Giaquinta, MD,a Tiziano Tallarita, MD,a Nunziata Sinagra, MD,a
Carla Virgilio, MD,a Domenico Zerbo, MD,a Peter Gloviczki, MD,b and
Massimiliano Veroux, MD, PhD,a Catania, Italy; and Rochester, Minn
Purpose: The purpose of this study was to evaluate the effect of primary balloon angioplasty (PBA) of cephalic veins with
diameter <2 mm on patency and maturation time of autogenous radiocephalic arteriovenous fistulae (AVF) for
hemodialysis.
Methods: Forty patients, all candidates for distal AVF, with a cephalic vein <2 mm, were randomized to two different
surgical procedures: (1) PBA of a long segment of the cephalic vein from the wrist up to the elbow (n  19); and (2)
hydrostatic dilatation (HD) of a short venous segment (5 cm) at the level of the anastomosis (n  21). PBA was
performed using a standard balloon 4  150 mm. Primary end points were primary patency and reintervention rates.
Secondary end points were maturation time and the rate of working AVF. Follow-up included physical and duplex
ultrasound (DUS) examinations at 1,4, and 8 weeks, and every 3 months thereafter.
Results:Risk factors were homogeneously distributed between the two groups. Mean vein diameter was 1.8 0.2 mm for
the PBA group and 1.7 0.2 mm for HD. Immediate success rate was 100% for PBA and 67% for HD groups (P .04).
Causes of failure in the HD group included early vein thrombosis in seven patients (33%). Mean fistula maturation time
was 32 days in the PBA group and 55 days in the HD group (P  .04). During the mean follow-up of 7 months, three
patients underwent drug-eluting balloon angioplasty for failure of AVF to mature due to stenosis (1 in the PBA group
and 2 in the HD group). Six-month reintervention rate was significantly lower in the PBA group (5%) compared with the
HD group (43%) (P  .02). At 6 months, primary patency rates were 95% in the PBA group and 57% in the HD group
(P  .01). Working AVF rate was 100% in the PBA vs 90% in the HD group.
Conclusions: PBA of very small cephalic veins during the creation of a distal AVF for hemodialysis is a safe and feasible
procedure. This technique assures excellent primary patency, maturation time, and dramatically decreases reintervention
rate. ( J Vasc Surg 2013;57:131-6.)
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wIn the past 10 years, the number of dialysis-dependent
patients has increased an estimated 3.2% each year. Autog-
enous arteriovenous fistula (AVF) has been shown to be
superior to prosthetic graft or catheter access in terms of
patient morbidity and mortality, and less expensive in terms
of maintenance.1-6 Although the National Kidney Foundation-
Kidney Disease Outcomes Quality Initiative Clinical
Practice Guidelines for Vascular Access1 stated that the
vascular access should be performed in all patients with
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http://dx.doi.org/10.1016/j.jvs.2012.07.047ndstage renal disease (ESRD) 4 to 6 months before
tarting chronic hemodialysis, to reduce the risk of sepsis
nd death related to the use of hemodialysis catheters, only
minority of patients have a well functioning AVF at the
ime of starting hemodialysis.7 The most important factor
imiting the AVF growth and patency is the availability of a
enous segment with adequate diameter: cephalic veins
maller than 2.5 mm in diameter have been reported to
ncrease immediate failure rate and to decrease primary
atency rate.8,9
The purpose of this study was to evaluate if primary
alloon angioplasty (PBA) of cephalic veins with a preop-
rative diameter of 2 mm could improve the primary
atency rate and maturation of autogenous distal AVFs.
ETHODS
This study was approved by the institutional review
oard of our institution. Clinical, anatomic, and procedural
ata of all consecutive patients with ESRD who underwent
VF creation between 2009 and 2011 were entered into an
nstitutional database. Inclusion criteria were radial artery
ith normal duplex ultrasound (DUS) parameters and
ephalic vein 2 mm in diameter. Exclusion criteria in-
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radial artery extensive disease that precluded the creation of
a distal autogenous AVF.
Patients were randomized on a 1:1 basis into two
groups according to the technique used to increase the vein
caliber (see Techniques). All patients signed a written in-
formed consent before their surgical procedure. One pa-
tient scheduled for PBA of the cephalic vein refused the
procedure and underwent a standard hydrostatic dilation of
the vein.
Preoperative work-up included physical examination
(including upper arm inspection with and without the
tourniquet and Allen test to evaluate the quality of the
collateral flow to the hand) andDUS. Parameters evaluated
by DUS were patency, diameter, and peak systolic velocity
(PSV) of the brachial and radial arteries and diameter,
patency, and depth of the cephalic vein. In particular, vein
diameter was measured by DUS with a tourniquet, inner
wall to inner wall. The nondominant upper limb was usu-
ally preferred, when feasible. Demographics, clinical char-
acteristics, and operative data were obtained from the med-
ical records. Medical therapy included acetylsalicylic acid
started at least 1 week before the procedure and continued
for 4 weeks after the procedure. Early postprocedure period
was defined as occurring within the first 30 days or within
hospital stay. Technical immediate success was defined as a
presence of a thrill during palpation and a bruit at auscul-
tation, associated with a PSV200 cm/s by intraoperative
DUS at the site of anastomosis. Follow-up period was
defined as after 30 days or dismissal, and consisted of
clinical examination and DUS at 1, 4, and 8 weeks after the
procedure, and every 3 months thereafter. Diminished or
absent thrill and decreased flow rate (250 mL/min) were
considered an indication for early evaluation beyond the
established protocol of surveillance. A significant stenosis was
defined as a PSV 400 cm/s by DUS or a luminal diameter
reduction of 50% on angiography.10 Stenosis was considered
in the peri-anastomotic site and at venous outflow levels.
Primary patency (intervention-free access survival) was de-
fined as the interval from time of access placement to any
interventiondesigned tomaintain or re-establish patency or to
access thrombosis or the time of measurement of patency.11
Fistula failure was defined as any event that required an inter-
vention tomaintain or re-establish patency, including stenosis,
thrombosis, hemorrhage, and ischemia of the hand, leading to
a new access.Maturation timewas defined as the interval from
the AVF creation to first successful hemodialysis use.Working
AVF was defined as the AVF useful for hemodialysis access.
Primary end points were 6-month primary patency of
AVF and reintervention rates. Secondary end points in-
cluded maturation time and the rate of working AVFs.
Surgical techniques. All surgical procedures have
been performed by the same surgeon (P.V.). All patients
received a systemic anticoagulation using 2500 IU of hep-
arin 3 minutes before clamping the cephalic vein and the
radial artery.
No intravenous or local vasodilators were used. Pa-
tients were randomized into two groups: na. Hydrostatic dilatation (HD): after isolation of about 5
cm of cephalic vein at the wrist with ligation of collateral
veins, the vein was dilated by injection of high-pressure
sterile solution through a syringe 20 mL and 16-gauge
plastic cannula to achieve the final diameter of 4 mm.
The anastomosis was performed end-to-side with the
radial artery, with 7/0 polypropylene running sutures.
. PBA: after isolation of 3 to 4 centimeters of cephalic
vein, a guidewire 0.018 inches (V-18; Boston-Scientific,
Natick, Mass) was introduced through the cephalic vein
and advanced up to the elbow under direct palpation, or
DUS guidance in cases of deep cephalic vein. A non-
compliant balloon, 4 mm  150 mm (Pacific Extreme;
Medtronic-Invatec, Frauenfeld, Switzerland), was in-
troduced and gently inflated to 12 atmospheres of pres-
sure for a period of 60 seconds, from the elbow to the
level of the anastomosis (Fig 1, A), to achieve the final
diameter of 4 mm. The anastomosis was performed
end-to-side with 7/0 polypropylene running sutures
(Fig 1, B). After declamping, the cephalic vein was
evaluated by intraoperative DUS to assure that the
required vein diameter was achieved. In case of incom-
plete segmental vein dilatation, a second angioplasty,
using the same balloon, was performed through a col-
lateral branch of the cephalic vein.
Statistical analysis. Patency was analyzed using
aplan-Meier estimator. The Pearson 2 or Fisher exact
est was used for analysis of categorical variables. Differ-
nces between means were tested with two-sided t-test,
he Wilcoxon rank-sum test, or the Mann-Whitney U
est. A value of P  .05 was used to determine statistical
ignificance.
ESULTS
During the study period, 130 patients with ESRD under-
ent AVF creation. Among these, 40 patients met the criteria
f this study. Patients’ characteristics were similar between the
wo groups and are summarized in the Table. There were no
ifferences in terms of cardiovascular risk factors, including
ypertension, hyperlipidemia, tobacco use, coronary artery
isease, and chronic obstructive pulmonary disease be-
ween the two groups. Of the 40 procedures, 19 (47%)
ere performed using a PBA of the cephalic vein, whereas
n 21 cases (53%), a hydrostatic dilatation was performed to
ncrease the vein caliber.
Immediate success rate was 100% for PBA and 67% for
D groups. Causes of failure included early AVF throm-
osis in seven patients (33%). Immediate surgical revision
as performed in all cases, including thrombectomy of the
nastomosis and the cephalic vein, combined with plain old
alloon angioplasty (POBA) of the cephalic vein for the
ntire length of the forearm. Finally, a new anastomosis was
erformed in all patients.
During the mean follow-up of 7 months (range, 1-15
onths), three patients underwent reintervention for ste-
osis (one in the PBA group and two in the HD group).
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Volume 57, Number 1 Veroux et al 133Stenosis was found at the anastomotic level in two cases and
close to the anastomosis in one.
All patients underwent angiographic evaluation of the
vascular access, followed by percutaneous transluminal an-
gioplasty (PTA). The PTA was performed by proximal
catheterization of the AVF with the introduction of 4 Fr
sheaths. The vessel was dilated using a 0.018-inch guide-
wire (V-18 Boston-Scientific) and a drug-eluting balloon
(DEB) (In Pact Amphirion; Medtronic/Invatec, Frauen-
feld, Switzerland). The DEB was maintained insufflated for
120 seconds using a pressure ranging from 8 to 12 atm.
DEB-PTA was successful in two patients. In one patient
(HD group), a surgical approach with redoing the anasto-
mosis to a more proximal level of the cephalic vein was
performed. Six-month primary patency rate was 95% and
Fig 1. A, Balloon dilatation of a long segment of the cephalic
vein. B, Final overview of the working arteriovenous fistula (AVF).57% for the PBA group and the HD group, respectively cFig 2). The reintervention rate was 5% in the PBA group vs
3% in the HD group (P  .02). Mean fistula maturation
ime was 32 days (range, 21-38 days) in the PBA group and
5 days (range, 34-60 days) in the HD group (P .04). A
orking AVF was obtained in 19 patients (100%) in the
BA group and 19 (90%) in the HD group (P  .5).
ISCUSSION
This study demonstrated that PBA of cephalic veins2
m may improve the medium-term patency rate of autog-
nous distal AVF compared with standard hydrostatic tech-
ique.
The goals of the National Kidney Foundation-Kidney
isease Outcomes Quality Initiative Clinical Practice
uidelines for Vascular Access were to increase the preva-
ence of autogenous arteriovenous access placement to 66%
y 2009 and to prolong the use of existing accesses by early
ysfunction detection.12 Ideally, every patient should initi-
te dialysis with a mature fistula suitable for cannulation.
his requires a number of intermediate steps, including
re-ESRD care by a nephrologist, pre-ESRD access sur-
ery, adequate fistula maturation, and successful fistula
annulation by the dialysis staff. Omission of any of these
teps results in a patient who initiates dialysis with a central
enous catheter. Although autologous AVF is considered
he gold standard, the reported 1-year patency rates vary
rom 36% to 62.5%, with the vein diameter being the most
mportant factor affecting patency8: using smaller veins has
esulted in an increased number of reinterventions and
ailed fistulae.5 On the other hand, native fistulae fail to
ature at higher rates than do grafts13-16 and this may
able. Characteristics of 40 patients undergoing primary
alloon angioplasty (PBA) or hydrostatic dilatation (HD)
or autogenous arteriovenous fistula (AVF) creation
atient characteristics
PBA
n  19 (%)
HD
n  21 (%)
P
value
ale 13 (68) 16 (76) .80a
emale 6 (32) 5 (24)
ean age (mean  SD) 55  8 54  8 .30b
ypertension 19 (100) 21 (100) 1.0a
yperlipidemia 15 (79) 13 (62) .50a
obacco use 11 (58) 11 (52) .70a
oronary artery disease 8 (42) 7 (33) .60c
eripheral artery disease 8 (42) 6 (29) .50c
hronic pulmonary disease 5 (26) 5 (24) 1.0c
iabetes 6 (32) 4 (19) .30c
ialysis 13 (68) 4 (19) .20c
o dialysis 6 (32) 4 (19) .30c
rterial diameter (mean 
SD)
1.8  0.4 1.9  0.3 .80b
ein diameter (mean 
SD)
1.8  0.2 1.7  0.2 .78b
D, Standard deviation.
Chi-square test used.
t-test used.
Fisher exact test used.ounterbalance the above-mentioned advantages.
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January 2013134 Veroux et alDe Marco Garcia et al17 described an interesting tech-
nique of ballooning of a short segment of cephalic vein
(from midforearm to the wrist, length from 4 to 12 cm) at
the time of fistula creation, in a subgroup of patients with a
cephalic vein diameter3mm.However, 53 of 62 patients
needed repeated POBA under fluoroscopy at 2, 4, and 6
weeks after AVF creation: failure in AVF maturation was
probably related to the high resistances of the distal nondi-
lated small cephalic vein (from the midforearm to the
elbow).
In contrast, in our study, we have performed a balloon-
ing of a longer segment of cephalic vein from the wrist to
the elbow, before the AVF creation: this resulted in a
well-functioning AVF even in patients with very small
cephalic vein (2 mm). Moreover, this technique allowed
us to achieve a low resistance venous outflow that was
associated with an excellent 6-month primary patency and
working AVF rate (95% and 100%, respectively).
Although the concept of multiple ballooning during
the maturation time can be appealing, patients are exposed
to the risks of multiple angiograms, renal function deterio-
ration, and embolism. Repeated ballooning may also cause
intimal injury, which increases the risk of restenosis and
thrombosis. Finally, this technique is highly costly and not
comfortable for the patients.
The strength of our technique is in that it is easily
reproducible, not expensive, and avoids the need for mul-
tiple angiograms. In our study, the achieved cephalic vein
diameter of 4 mm for the entire length of the forearm was
Fig 2. Patency and working fistula rates at 6 month
(PBA; n  19) or hydrostatic dilatation (HD; n  21easily maintained over the time by the arterial blood pres- cure, creating favorable conditions for a working AVF.
oreover, the very low reintervention rate (5%) in our PBA
roup showed that dilatation of a longer segment of the
ephalic vein at the time of AVF creation is highly effective,
voiding the need for multiple late PTAs, as reported in the
tudy by De Marco Garcia et al.17
In our series, 6-month primary patency in the HD
roup was significantly lower than in the PBA group (57%
s 100%; P .04). In these patients, the key factor affecting
he patency of AVF was the high resistance venous outflow,
ecause there were no reported technical defects at the level
f the anastomosis. Surgical thrombectomy combined with
dilatation of the upper part of the cephalic vein with a
oncompliant balloon resulted in an excellent working
VF rate of 90%.
Several studies18-20 have provided evidence that active
urveillance and pre-emptive repair of a subclinical stenosis
educes the thrombosis rate and prolongs the functional life
f mature forearm AVFs.
In the recent literature, endovascular therapy has been
ncreasingly considered as a first choice of treatment for
VF late stenosis. Although the technical success has been
eported to be very high, patency rates have been moderate
t best.21 In a series of 536 POBAs performed for treatment
f vascular access stenosis, the technical success rate was
4%. However, the patency rate had dropped to 38% after 1
ear.22 In another series, 61% of patients (48 of 79) under-
ent a second PTA during follow-up due to the failure of
he first POBA.23 In a recent nonrandomized study, surgi-
40 patients undergoing primary balloon angioplasty
autogenous arteriovenous fistula (AVF) creation.s ofal and endovascular treatment of anastomotic and juxta-
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gery showed similar results, but repeat procedures were
more frequent with angioplasty.23 Additional stent place-
ment might also be beneficial in patients with autologous
AVF stenosis, but data are lacking.
Due to the high rate of restenosis associated with
POBA of AVF,23 we used DEB to treat re-stenosis of
vascular access, with promising results.
Medical therapy may play an important role in prevent-
ing early AVF thrombosis and optimizing fistula matura-
tion. Several small placebo-controlled trials showed lower
rates of early fistula thrombosis with short-term use of
antiplatelet agents in the postoperative period.24-30
Recently, Dember et al31 reported on the use of clopi-
dogrel in the perioperative period to reduce AVF throm-
bosis without increasing bleeding events. However, the
beneficial effect on thrombosis was not accompanied by an
increase in the proportion of fistulae that were suitable for
dialysis.31
Early patency is necessary but not sufficient for fistula
maturation, suggesting that thrombosis may be a manifes-
tation rather than a cause of maturation failure. We used
acetyl salicylic acid 1 week before and at least 4 weeks after
the procedure. In our experience, antiplatelet drugs did not
reduce thrombotic events in the HD group, emphasizing
that hemodynamic and anatomic defects play a more sig-
nificant role in determining fistula thrombosis rather than
the type of prophylactic medical therapy.
Our technique has the great potential to improve the
pool of candidates for autologous vascular access for hemo-
dialysis by including those patients who have been previ-
ously discarded for distal autogenous AVF due to small
distal cephalic veins. However, there are several shortcom-
ings that need to be discussed. First of all, the small sample
size and the short follow-up did not allow us to reach
definitive conclusions, because future stenosis could poten-
tially be encountered during a long-term surveillance. Sec-
ond, the strict selection criterion of this study prevents the
use of this technique on a large number of patients.
In conclusion, PBA of very small cephalic veins per-
formed before the creation of a distal AVF for hemodialysis
is a safe and feasible procedure. This technique is associated
with excellent patency and maturation, dramatically de-
creases the need for reintervention, and is superior to the
standard hydrostatic dilatation technique.
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